摘要
目的为临床治疗间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌(NSCLC)提供参考。方法检索布格替尼的相关文献,总结其化学结构、临床研究及不良反应方面的研究进展。结果从化学结构上看,布格替尼能与目标蛋白结合,使其具有更好的靶向性。相较于第1代ALK-TKIs克唑替尼,其治疗ALK阳性NSCLC及脑转移ALK阳性NSCLC患者的客观缓解率、无进展生存期、总生存期均更有优势,常见不良反应为胃肠道、血液系统、循环系统、呼吸系统反应。结论布格替尼作用靶点明确,在控制ALK阳性NSCLC患者的脑转移、延长生存期方面具有优势。
Objective To provide a reference for the clinical treatment of anaplastic lymphoma kinase(ALK)-positive non-small cell lung cancer(NSCLC).Methods The literature related to brigatinib were searched,and the research progress of its chemical structure,clinical trials,and adverse drug reactions was summarized.Results In view of the chemical structure of brigatinib,it could bind to the target protein,which made the drug better targeted.Compared with crizotinib,the first-generation ALK-TKIs,brigatinib has advantages in the objective response rate(ORR),progression free survival(PFS),and overall survival(OS)of patients with ALK-positive NSCLC and patients with brain metastasis complicated with ALK-positive NSCLC.The common adverse reactions are in the digestive system,blood system,circulatory system,respiratory system,etc.Conclusion Brigatinib has a clear target of action and has advantages in controlling brain metastasis and prolonging the survival of patients with ALK-positive NSCLC.
作者
郑晓辉
赵振营
张惠娟
史桂玲
ZHENG Xiaohui;ZHAO Zhenying;ZHANG Huijuan;SHI Guiling(Tianjin Union Medical Center,Tianjin,China 300121)
出处
《中国药业》
CAS
2023年第9期I0001-I0004,共4页
China Pharmaceuticals
基金
国家自然科学基金[81503127]。
